937.7500 -9.55 (-1.01%)
NSE Sep 09, 2025 15:31 PM
Volume: 73,236
 

ICICI Securities Limited
Alembic Pharma’s (Alembic) Q2FY23 performance was broadly in line with our estimates. Revenue grew 14.1% YoY to Rs14.8bn (I-Sec: Rs14.4bn). India business (excl. one-time benefits) grew ~11% YoY.
Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.
More from Alembic Pharmaceuticals Ltd.
Recommended